- Home
- LARK vs PROK Comparison
LARK vs PROK Comparison
Compare LARK & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LARK
- PROK
- Stock Information
- Founded
- LARK 1885
- PROK 2015
- Country
- LARK United States
- PROK United States
- Employees
- LARK N/A
- PROK N/A
- Industry
- LARK Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LARK Finance
- PROK Health Care
- Exchange
- LARK Nasdaq
- PROK Nasdaq
- Market Cap
- LARK 167.5M
- PROK 94.9M
- IPO Year
- LARK N/A
- PROK N/A
- Fundamental
- Price
- LARK $29.68
- PROK $0.70
- Analyst Decision
- LARK
- PROK Buy
- Analyst Count
- LARK 0
- PROK 4
- Target Price
- LARK N/A
- PROK $5.00
- AVG Volume (30 Days)
- LARK 31.0K
- PROK 1.2M
- Earning Date
- LARK 04-30-2025
- PROK 05-16-2025
- Dividend Yield
- LARK 2.96%
- PROK N/A
- EPS Growth
- LARK 27.69
- PROK N/A
- EPS
- LARK 2.59
- PROK N/A
- Revenue
- LARK $60,798,000.00
- PROK $76,000.00
- Revenue This Year
- LARK N/A
- PROK N/A
- Revenue Next Year
- LARK N/A
- PROK N/A
- P/E Ratio
- LARK $11.20
- PROK N/A
- Revenue Growth
- LARK 9.30
- PROK N/A
- 52 Week Low
- LARK $17.53
- PROK $0.46
- 52 Week High
- LARK $31.04
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- LARK 55.52
- PROK 41.42
- Support Level
- LARK $28.40
- PROK $0.94
- Resistance Level
- LARK $31.00
- PROK $0.77
- Average True Range (ATR)
- LARK 1.10
- PROK 0.12
- MACD
- LARK -0.14
- PROK -0.01
- Stochastic Oscillator
- LARK 41.75
- PROK 17.63
About LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.